Suset Isabel Oropesa
Suset Isabel Oropesa has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Viada
Center of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba
1 shared publication - Delmis Alvarez
Virology Department, Institute of Tropical Medicine “Pedro Kourí”, Autopista Novia del Mediodía Km 6, PO Box 601, Marianao 13, Havana City, Cuba
1 shared publication - Licel de Los Angeles Rodriguez Lay
Virology Department Institute of Tropical Medicine Pedro Kouri (IPK) Havana Cuba
1 shared publication - Madelyn Garcés1 shared publication
- Margarita Gascón1 shared publication
- Maria Guadalupe Guzman
Institute of Tropical Medicine Pedro Kouri, PAHO/WHO Collaborating Center for Dengue and its Control, Havana, Cuba
1 shared publication
Latest Publications
- Open Access
- 15 September 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (3) , 16
Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.
- 15 September 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (3) , 16
Open AccessPost-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.